<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525239</url>
  </required_header>
  <id_info>
    <org_study_id>DK66999</org_study_id>
    <nct_id>NCT00525239</nct_id>
  </id_info>
  <brief_title>HIV Antiretroviral Drugs and Metabolism</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis 1: Ritonavir-based regimens increase triglycerides and VLDL by both increasing
      VLDL production and decreasing VLDL clearance.

      Specific Aim 1A: To quantify the effect of ritonavir on VLDL production and clearance using
      stable isotope turnover and other clearance methods.

      Specific Aim 1B: To determine the composition of the triglyceride rich particles.

      Protocol 1: The effects of ritonavir-based regimens on VLDL production, VLDL clearance and
      triglyceride-rich lipoprotein composition in healthy normal volunteers. HIV-seronegative
      volunteers will be studied before and at the end of four weeks of taking ritonavir,
      lopinavir/ritonavir or atazanavir/ritonavir.

      Hypothesis 2: NNRTI drugs do not increase HDL by increasing apo AI production, but rather by
      decreasing apo AI clearance, prolonging time in circulation.

      Specific Aim 2A: To determine the composition of HDL before and after NNRTI and assess its
      function.

      Specific Aim 2B: To quantify the effect of NNRTI on apo AI production and clearance using
      stable isotopes.

      Specific Aim 2C: To determine if the NNRTI induced increase in HDL is accompanied by
      improvement in flow mediated vasodilation and circulating markers of endothelial function
      Protocol 2A: The effects of efavirenz on HDL composition, HDL function, apo AI production,
      apo AI clearance, flow mediated vasodilation and circulating markers of endothelial
      dysfunction in healthy normal volunteers. HIV-seronegative volunteers will be studied before
      and at the end of six weeks of taking efavirenz.

      Protocol 2B: The effects of starting an efavirenz-based regimen on HDL composition, HDL
      function, apo AI production, apo AI clearance, flow mediated vasodilation and circulating
      markers of endothelial dysfunction in patients with HIV infection. HIV-infected patients
      whose care providers have prescribed an efavirenz-based regimen will be studied before and
      after six weeks of starting efavirenz.

      Hypothesis 3: Ritonavir-based PI regimens impair insulin secretion. Specific Aim 3: To
      determine which ritonavir-based PI regimens alter insulin secretion.

      Protocol 3: The effects of ritonavir-based regimens on insulin secretion in healthy normal
      volunteers. HIV-seronegative volunteers will be studied before and at the end of four weeks
      of taking ritonavir, lopinavir/ritonavir or atazanavir/ritonavir.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2004</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of HIV Protease Inhibitors on Glucose Metabolism by Hyperglycemic Clamp</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of HIV Protease Inhibitors on Oral Glucose Tolerance Test</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1: Ritonaivr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre and post ritonavir, lopinavir/ritonavir or atazanavir/ritonavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz</intervention_name>
    <description>100 mg, twice daily, for four weeks</description>
    <arm_group_label>1: Ritonaivr</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Protocols 1, 2A and 3 HIV negative, healthy normal volunteers, age &gt; 18 years old.

        Protocol 2B HIV-infected subjects, age &gt; 18 years old and documented to have HIV-1
        infection for â‰¥ 6 months, being started on efavirenz by their health care provider.

        Exclusion Criteria:

        Protocols 1, 2A and 3 Coronary artery disease, peripheral vascular disease, impaired
        fasting glucose (glucose &gt; 100 mg/dl), obese (BMI &gt; 30), dyslipidemia (triglycerides &gt; 190
        mg/dl, LDL-C &gt; 190), anemia (Hct &lt; 39), hypertension (BP&gt; 140/90 mmHg or on medication),
        blood pressure &lt;100 mmHg, renal disease (creatinine &gt; 1.6), LFT &gt; ULN, or use within 30
        days of systemic glucocorticoids, anabolic steroids, growth hormone, niacin,
        antipsychotics, or lipid lowering medications. Women will be tested for pregnancy
        immediately prior to each inpatient study and excluded if pregnant. For Specific Aim 2,
        additional exclusion criteria include history of depression requiring treatment, psychosis,
        hallucinations or delusions; use of cGMP specific phosphodiesterase 5 inhibitors (e.g.,
        sildenafil) within 7 days of study; or history of adverse reaction to nitrates.

        Protocols 1, 2A and 3 Currently on an NNRTI, coronary artery disease, peripheral vascular
        disease, recent opportunistic infection (within two months), impaired fasting glucose
        (glucose &gt; 100 mg/dl) or diabetes, anemia (Hct &lt; 39), hypertension (BP &gt; 140/90 mmHg or on
        medication), blood pressure &lt;100 mmHg, renal disease (Creatinine &gt; 1.6), LFT &gt; 2x ULN, use
        of cGMP specific phosphodiesterase 5 inhibitors (e.g., sildenafil) within 7 days of study,
        history of adverse reaction to nitrates, use within 30 days of anabolic steroids, systemic
        glucocorticoids, growth hormone, niacin, antipsychotics, or lipid lowering medications.
        Women will be tested for pregnancy immediately prior to each inpatient study and excluded
        if pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Grunfeld, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern California Institute for Research and Education</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carl Grunfeld, M.D., Ph.D.</last_name>
    <phone>415-750-2005</phone>
    <email>carl.grunfeld@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mae Pang, R.N. M.S.N</last_name>
    <phone>415-750-2005</phone>
    <email>miyin.pang@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Veterans Affairs Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mae Pang, RN, MSN</last_name>
      <phone>415-750-2005</phone>
      <email>miyin.pang@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lyda Galvez</last_name>
      <phone>415-750-2005</phone>
      <email>lyda.galvez@va.gov</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001 May 4;15(7):F11-8.</citation>
    <PMID>11399973</PMID>
  </results_reference>
  <results_reference>
    <citation>Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002 Mar 29;16(5):F1-8.</citation>
    <PMID>11964551</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M, Grunfeld C. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004 Mar 5;18(4):641-9.</citation>
    <PMID>15090769</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee GA, Mafong DD, Noor MA, Lo JC, Mulligan K, Schwarz JM, Schambelan M, Grunfeld C. HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr. 2004 May 1;36(1):645-7.</citation>
    <PMID>15097312</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwarz JM, Lee GA, Park S, Noor MA, Lee J, Wen M, Lo JC, Mulligan K, Schambelan M, Grunfeld C. Indinavir increases glucose production in healthy HIV-negative men. AIDS. 2004 Sep 3;18(13):1852-4.</citation>
    <PMID>15316349</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee GA, Rao MN, Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr HIV/AIDS Rep. 2005 Feb;2(1):39-50. Review.</citation>
    <PMID>16091248</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee GA, Lo JC, Aweeka F, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis. 2006 Sep 1;43(5):658-60. Epub 2006 Jul 26.</citation>
    <PMID>16886163</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee GA, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, Schambelan M, Grunfeld C. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS. 2007 Oct 18;21(16):2183-90.</citation>
    <PMID>18090045</PMID>
  </results_reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <last_update_submitted>March 15, 2011</last_update_submitted>
  <last_update_submitted_qc>March 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Carl Grunfeld, M.D., Ph.D., Principal Investigator</name_title>
    <organization>Northern California Institute for Rerseach and Education</organization>
  </responsible_party>
  <keyword>Lipids</keyword>
  <keyword>lipoproteins</keyword>
  <keyword>VLDL</keyword>
  <keyword>triglycerides</keyword>
  <keyword>apo B100</keyword>
  <keyword>HDL</keyword>
  <keyword>apo A1</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>hyperglycemic clamp</keyword>
  <keyword>HIV-seronegative Volunteers</keyword>
  <keyword>HIV-infected subjects starting an efavirenz-based regimen</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

